Biotron Limited (Biotron) is leading the way in the development of revolutionary new treatments for serious viral diseases such as HIV and Hepatitis C virus (HCV). Biotron has an impressive pipeline of clinical programs developing first-in-class antiviral drugs.

Biotron’s lead drug, BIT225, is a viroporin inhibitor in development for treatment of HCV and HIV infections. The drug has successfully passed through three human trials, with the successful recent completion of a Phase 2a trial of BIT225 in HCV-infected patients in combination with the current approved treatment (Interferon and Ribavirin). A Phase Ib/2a HIV trial is currently in progress and anticipated to conclude in early 2012.